Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-02-15
2005-02-15
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S307000, C544S335000, C546S145000, C546S146000
Reexamination Certificate
active
06855717
ABSTRACT:
Compounds of formula (I):wherein:R2represents a hydrogen atom or a C1-4alkyl group;q is 1 or 2;A represents a group of formula (a) or (b)whereinT, U, V and Y independently represent CH or a nitrogen atom;R5is a group selected from: a hydrogen or halogen atom, cyano, C1-4alkyl or C1-4alkoxy groups is 1 or 2;Ar2represents an optionally substituted phenyl ring or an optionally substituted 5- or 6-membered aromatic heterocyclic ring; and salts thereof. The compounds are useful for the treatment of conditions which require modulaton of a dopamine receptor such as schizophrenia.
REFERENCES:
patent: 6465485 (2002-10-01), Branch et al.
Levant, The D3 Dopamine Receptor: Neurobiology and Potential Clinical Relevance, Pharmacological Reviews, vol. 49, No. 3, pp. 231-252, 1997.
Branch Clive Leslie
Johnson Christopher Norbert
Stemp Geoffrey
Furman Theodore R.
Rao Deepak
SmithKline Beecham plc
Stein-Fernandez Nora
Winslow Andrea
LandOfFree
Tetrahydroisoquinoline derivatives as modulators of dopamine... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tetrahydroisoquinoline derivatives as modulators of dopamine..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tetrahydroisoquinoline derivatives as modulators of dopamine... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3493307